Cargando…

Overcoming docetaxel resistance in prostate cancer: a perspective review

The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy associated with a survival benefit in castrate-resistant prostate cancer. Toxicity is typical of other cytotoxic agents, with my...

Descripción completa

Detalles Bibliográficos
Autor principal: Hwang, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481557/
https://www.ncbi.nlm.nih.gov/pubmed/23118808
http://dx.doi.org/10.1177/1758834012449685